MedTrace Logo

Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones

NCT06003348 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-04-06

No results posted yet for this study

Summary

This study tests whether hydroxycitrate, a molecule closely related to citrate, can reduce calcium phosphate stone recurrence.

Conditions

  • Calcium Phosphate Kidney Stones

Interventions

DIETARY_SUPPLEMENT

OHCit- standard dose

Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.

DRUG

Potassium Citrate

10 mEq Extended-release tablets for oral use

DRUG

Placebo

Placebo

DIETARY_SUPPLEMENT

OHCit- low dose

Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • NAIM M MAALOUF · University of Texas Southwestern Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-13
Primary Completion
2028-05-31
Completion
2028-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06003348 on ClinicalTrials.gov